SEC Form 4 · accession 0001209191-15-085635
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abhay Joshi
Officer — Chief Operating Officer
Period of report
Dec 14, 2015
Accepted (ET)
Dec 16, 2015 · 6:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 14, 2015 | A | 34,375 | $0.00 | A | 34,375 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F2 | $36.32 | Dec 14, 2015 | A | 206,250 | A | — | Dec 13, 2025 | Common Stock | 206,250 | 206,250 | D |
Explanation of responses
- F1The restricted stock award shall vest in four (4) equal annual installments beginning on December 14, 2016, subject to the Reporting Person's Continuous Service (as defined by the Issuer's 2014 Inducement Plan (the "Plan")) on each vesting date.
- F2The shares subject to the stock option shall vest over a period of four years, with 25% of the underlying shares vesting on December 14, 2016 and 1/48 of the total number of underlying shares vesting each month over the remaining three years, subject to the Reporting Person's Continuous Service (as defined in the Plan) on each vesting date.